|
|
|
|
| LEADER |
01389 am a22002533u 4500 |
| 001 |
74543 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Efeyan, Alejo
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biology
|e contributor
|
| 100 |
1 |
0 |
|a Whitehead Institute for Biomedical Research
|e contributor
|
| 100 |
1 |
0 |
|a Koch Institute for Integrative Cancer Research at MIT
|e contributor
|
| 100 |
1 |
0 |
|a Efeyan, Alejo
|e contributor
|
| 100 |
1 |
0 |
|a Sabatini, David M.
|e contributor
|
| 700 |
1 |
0 |
|a Sabatini, David
|e author
|
| 245 |
0 |
0 |
|a mTOR and cancer: many loops in one pathway
|
| 260 |
|
|
|b Elsevier,
|c 2012-11-01T16:42:06Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/74543
|
| 520 |
|
|
|a The mammalian target of rapamycin (mTOR) is a master regulator of cell growth and division that responds to a variety of stimuli, including nutrient, energy, and growth factors. In the last years, a significant number of pieces have been added to the puzzle of how mTOR coordinates and executes its functions. Extensive research on mTOR has also uncovered a complex network of regulatory loops that impact the therapeutic approaches aimed at targeting mTOR.
|
| 520 |
|
|
|a Howard Hughes Medical Institute
|
| 520 |
|
|
|a National Institutes of Health (U.S.)
|
| 520 |
|
|
|a Human Frontier Science Program (Strasbourg, France)
|
| 546 |
|
|
|a en_US
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Current Opinion in Cell Biology
|
